EUVIMEDEUVIMED entdecken
Crossref

Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy

Yifan Zhao, Xiaomei Zhang, Meng Zhang, Ruiting Guo, Yi Zhang, Yedi Pu, Haibo Zhu, Pengjiang Liu, Yu Zhang, Xiaoyuan He, Cuicui Lyu, Hairong Lyu und 2 weitere

Annals of Hematology · 2024-03 · 103 (3) · 969-980

DOI: 10.1007/s00277-024-05617-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 12.01.2024. Verfasst von Yifan Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: The First Central Clinical College of Tianjin Medical University, Tianjin, 300380, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Leukemia, Myeloid, Acute, Neurotoxicity Syndromes. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cell therapy targeting CLL1 has been considered a potent weapon for patients with acute myeloid leukemia (AML). This study aims to evaluate the efficacy and toxicity of CLL1 CAR-T cell therapy in a larger cohort, with particular attention to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among the 32 patients assessed for efficacy, complete remission occurred in 71.88% (23/32) of cases and undetectable minimal residual disease in 14 patients. The CRS developed in all patients, with 8 individuals experiencing ICANS. Severe CRS and ICANS were observed in 11 and 2 patients, respectively. Furthermore, the Endothelial Activation and Stress Index (EASIX) and its derivatives measured before and after CLL1 CAR-T cell infusion were employed for predicting the severe complications. Significant differences were observed in EASIX scores on the day before lymphodepletion (Day BL, P = 0.023), -1 (P < 0.001), +1 (P < 0.001), and +3(P = 0.014); sEASIX scores on Day BL (P = 0.007), -1 (P < 0.001), +1 (P < 0.001), and +3 (P < 0.001); and mEASIX score on Day -1 (P = 0.004) between patients with mild and severe CRS/ICANS. Additionally, there was a significant difference in mEASIX scores between responders and non-responders on Day BL (P = 0.004) and Day -1 (P = 0.044). Our findings indicate that pre- and post-infusion assessments of EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS and treatment response following CLL1 CAR-T cell therapy, which can assist physicians in implementing preemptive treatment strategies for potential severe complications and screening patients who are suitable candidates for CLL1 CAR-T cell therapy. EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS following CLL1 CAR-T cell therapy. The preinfusion mEASIX scores of CLL1 CAR-T cells can effectively predict treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLeukemia, Myeloid, AcuteNeurotoxicity SyndromesHumansCytokine Release SyndromeCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

Acute myeloid leukemiaCAR-TCytokine release syndromeEASIXImmune effector cell-associated neurotoxicity syndrome

Substanzen

cell-associated neurotoxicityReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • The First Central Clinical College of Tianjin Medical University, Tianjin, 300380, China.
  • Nankai University School of Medicine, Tianjin, 300380, China.
  • Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China.
  • Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China. xxiiaao@126.com.
  • Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China. mingfengzhao@sina.com.

Zitieren

APA

Zhao, Y., Zhang, X., Zhang, M., Guo, R., Zhang, Y., Pu, Y., Zhu, H., Liu, P., Zhang, Y., He, X., Lyu, C., Lyu, H., Xiao, X., & Zhao, M. (2024). Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Annals of Hematology, 103(3), 969-980. https://doi.org/10.1007/s00277-024-05617-y

Vancouver

Zhao Y, Zhang X, Zhang M, Guo R, Zhang Y, Pu Y, et al. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Annals of Hematology. 2024;103(3):969-980. doi:10.1007/s00277-024-05617-y

BibTeX
@article{Zhao2024,
  author = {Zhao, Yifan and Zhang, Xiaomei and Zhang, Meng and Guo, Ruiting and Zhang, Yi and Pu, Yedi and Zhu, Haibo and Liu, Pengjiang and Zhang, Yu and He, Xiaoyuan and Lyu, Cuicui and Lyu, Hairong and Xiao, Xia and Zhao, Mingfeng},
  title = {Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy},
  journal = {Annals of Hematology},
  year = {2024},
  volume = {103},
  number = {3},
  pages = {969--980},
  doi = {10.1007/s00277-024-05617-y}
}
Kostenlos starten →